NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 3rd July 2009 A narrative review estimates that the incidence of statin-related myopathy in practice is higher than might be expected from data reported in clinical trials. Although a […]
Category Archives: Cardiovascular disease
NPC Archive Item: Ezetimibe and cancer — more reassuring data
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 1st July 2009 An analysis of post-marketing adverse event reports did not find any increased risk of cancer with ezetimibe▼ compared with statins, either alone or when taken in […]
NPC Archive Item: More data question the value of aspirin in primary prevention of CV disease
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 15th June 2009 This ATT meta-analywsis found that in the primary prevention of cardiovascular (CV) disease, the balance of benefits and risks with aspirin is unclear. While there appears […]
NPC Archive Item: June Drug Safety Update from MHRA/CHM
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The Drug Safety Update is an NHS Evidence accredited provider 11th June 2009 The MHRA and CHM have published the June edition of Drug Safety Update. This issue gives […]
NPC Archive Item: Standard dose statins reduce the risk of CHD in patients with familial hypercholesterolaemia
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 10th June 2009 This retrospective cohort study found that statins significantly reduced the risk of coronary heart disease (CHD) in patients with familial hypercholesterolaemia (FH), even though they were […]
NPC Archive Item: EMEA statement on possible interaction between clopidogrel and proton pump inhibitors
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 4th June 2009 Concomitant use of proton pump inhibitors (PPIs) and clopidogrel is not advisable unless absolutely necessary, the EU Committee for Medicinal products for Human Use (CHMP) and […]
NPC Archive Item: Current practice for monitoring and adjusting blood pressure treatment may be inappropriate
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 3rd June 2009 Two recent studies (Keenan et al 2009 and Law et al 2009) raise important concerns about current practice for routine monitoring of blood pressure. Firstly, using […]
NPC Archive Item: Review of ALLHAT concludes that a thiazide is still a good first choice antihypertensive drug
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 27th May 2009 Thiazide diuretics are unsurpassed as initial therapy for reduction of cardiovascular (including stroke) and renal risk, a review of ALLHAT has concluded. ALLHAT, still the largest […]
NPC Archive Item: WATCHing and wondering: no clear answers about antithrombotics in heart failure
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 27th May 2009 The WATCH study compared adjusted dose warfarin, aspirin and clopidogrel in patients with heart failure. The study was underpowered but does not provide strong evidence that […]
NPC Archive Item: NICE publishes guidance on rivaroxaban▼ for prevention of VTE after hip and knee surgery
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 5th May 2009 NICE technology appraisal guidance 170▼ recommends oral rivaroxaban (Xarelto®) as an option for the prevention of venous thromboembolism (VTE) in adults having elective total hip replacement surgery or […]